companiesCompany
Arsenal Biosciences
Programmable CAR-T company using logic gates so cells fire only when two tumour proteins are present; AB-2100 (PSMA + CA9) is in phase 1/2 for kidney cancer.
AB-2100 uses a synthetic AND gate (PSMA and CA9), shRNA armouring against TME suppression, and a synthetic pathway activator; phase 1/2 in clear-cell RCC after IO and VEGF therapy (NCT06245915, primary completion 2026). AB-1015 in ovarian cancer. Raised $325M with Regeneron and BMS participation.